Nope, but cheap IP is for other Pharma companies. Be mindful of other companies making progression in the space and the possibility that someone picks this up in a fire sale for an easy route to a well patented approach to reliable potency assays in MSc delivery - a hurdle for some companies with regulators in the space.
$7 million mkt cap would be less than the stationary expenses of some of the larger Pharmas'.
Nope, but cheap IP is for other Pharma companies. Be mindful of...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.772M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 142 | 1 |
View Market Depth
| Last trade - 07.02am 08/08/2024 (20 minute delay) ? |
| CMB (ASX) Chart |
Day chart unavailable